We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Magnesium therapy in borderline hypertension.
- Authors
Kisters, Klaus; Wessels, Franz; Nguyen, Michael Q.; Mitchell, Anna; Gremmler, Bernhard; Funke, Christoph; Baraliakos, Xenofon; Kask, Bartholomäus; Hausberg, Martin; Hunger, Robert; Liebscher, Dierck-H.; Liebscher, Ursula; Tokmak, Faruk
- Abstract
A magnesium deficiency plays a pathogenetic role in the development of primary hypertension. We have measured plasma and intracellular Mg++ levels in erythrocytes of 18 untreated borderline hypertensive patients, and in 35 untreated normotensive healthy subjects as controls. In patients intracellular Mg++ content was significantly lower (1.61 ± 0.09 mmol/l ± SD), than in controls (1.84 ± 0.14 mmol/l, p < 0.05), After 12 - 15 weeks of an oral supplementation with 240 - 480 mg Mg++/day, the erythrocyte Mg++ content had increased significantly in the borderline hypertensive group (1.78 ± 0.11 mmol/l, p < 0.05). There was no significant difference between the normotensive and borderline hypertensive group in plasma Mg++ concentrations (0.87 ± 0.13 vs. 0.83 ± 0.17 mmol/l). Systolic and diastolic blood pressure values of the borderline hypertensive group also normalized after oral Mg++ administration (before therapy: 147.6 ± 8.5/87.2 ± 4.4 mmHg: after therapy: 137.2 ± 4.6/83.8 ± 3.4 mmHg, p < 0.05). We conclude that Mg++ deficient borderline hypertensives can benefit from magnesium supplementation with regard to high blood pressure and quality of life.
- Subjects
THERAPEUTIC use of magnesium; MILD hypertension; ERYTHROCYTES; BLOOD pressure measurement; ANALYSIS of variance; PATIENTS
- Publication
Trace Elements & Electrolytes, 2012, Vol 29, Issue 2, p113
- ISSN
0946-2104
- Publication type
Article
- DOI
10.5414/TEX01201